Insider · CIK 0001568077
Tomer Kariv
Files at KROS (Keros Therapeutics, Inc.). First filing Oct 17, 2025, latest Oct 17, 2025.
Tomer Kariv files SEC Form 4 as director and 10% owner at KROS (Keros Therapeutics, Inc.). Since Oct 17, 2025, Tomer Kariv has reported 0 open-market buys worth $0 and 1 open-market sell worth $85M, the latest filed on Oct 17, 2025.
A track record needs three past buys with six months of prices behind them; Tomer Kariv has 0, so none is measured yet.
The newest scored trade: sold $85M of KROS on Oct 15, 2025, filed Oct 17, 2025, scored 78 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $85M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KROS: Keros Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 78Notable | Keros Therapeutics, Inc. | $85M 4,787,331 shares | -210% | +52% from low-79% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | KROS Keros Therapeutics, Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax (Israel) IV, L.P. | -2,284,612 | $17.75 | $41M | 0 | Oct 17, 2025 |
| Oct 15, 2025 | KROS Keros Therapeutics, Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax (Cayman) IV, L.P. | -1,121,045 | $17.75 | $20M | 0 | Oct 17, 2025 |
| Oct 15, 2025 | KROS Keros Therapeutics, Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax (China) IV, L.P. | -1,226,412 | $17.75 | $22M | 0 | Oct 17, 2025 |
| Oct 15, 2025 | KROS Keros Therapeutics, Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: By Pontifax Late Stage Fund, L.P. | -155,262 | $17.75 | $2.8M | 0 | Oct 17, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Common Stock | +5,250 | $0.00 | $0 | 5,250 | Jun 6, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,500 | $0.00 | $0 | 10,500 | Jun 6, 2025 |
Questions about Tomer Kariv
Answered from the filings on this page, as of the latest one.
Is Tomer Kariv buying or selling?
In the last 12 months Tomer Kariv reported 0 open-market buys worth $0 and 1 open-market sell worth $85M on SEC Form 4; the latest was sold $85M of KROS on Oct 15, 2025. Grants, option exercises and tax withholding are not counted.
How did Tomer Kariv's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Tomer Kariv has 0.
Where does Tomer Kariv file Form 4?
Tomer Kariv has filed Form 4 at KROS (Keros Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.